These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16648225)

  • 1. Methylphenidate improves aspects of executive function in African American children with ADHD.
    Hazel-Fernandez LA; Klorman R; Wallace JM; Cook S
    J Atten Disord; 2006 May; 9(4):582-9. PubMed ID: 16648225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Huang YS; Yeh CB; Chen CH; Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):164-178. PubMed ID: 33395356
    [No Abstract]   [Full Text] [Related]  

  • 4. A pilot study: differential effects of methylphenidate-OROS on working memory and attention functions in children with attention-deficit/hyperactivity disorder with and without behavioural comorbidities.
    Rubio B; Hernández S; Verche E; Martín R; González-Pérez P
    Atten Defic Hyperact Disord; 2011 Mar; 3(1):13-20. PubMed ID: 21432614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.
    Cho SC; Kim BN; Cummins TD; Kim JW; Bellgrove MA
    J Psychopharmacol; 2012 Mar; 26(3):380-9. PubMed ID: 21628343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.
    Jain R; Babcock T; Burtea T; Dirks B; Adeyi B; Scheckner B; Lasser R; Renna J; Duncan D
    Adv Ther; 2013 May; 30(5):472-86. PubMed ID: 23681505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Wigal SB; Greenhill LL; Nordbrock E; Connor DF; Kollins SH; Adjei A; Childress A; Stehli A; Kupper RJ
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):562-9. PubMed ID: 25470572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.
    Chou WJ; Chen SJ; Chen YS; Liang HY; Lin CC; Tang CS; Huang YS; Yeh CB; Chou MC; Lin DY; Hou PH; Wu YY; Liu HJ; Huang YF; Hwang KL; Chan CH; Pan CH; Chang HL; Huang CF; Hsu JW
    J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):215-25. PubMed ID: 22537358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR) in Preschool Children with Attention-Deficit/Hyperactivity Disorder.
    Childress AC; Kollins SH; Foehl HC; Newcorn JH; Mattingly G; Kupper RJ; Adjei AL
    J Child Adolesc Psychopharmacol; 2020 Mar; 30(2):58-68. PubMed ID: 32125903
    [No Abstract]   [Full Text] [Related]  

  • 11. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI; Bijlenga D; Boonstra AM; Breuk M; Pardoen WF; Beekman AT; Kooij JJ
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):519-28. PubMed ID: 24508533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.
    Pelham WE; Gnagy EM; Burrows-Maclean L; Williams A; Fabiano GA; Morrisey SM; Chronis AM; Forehand GL; Nguyen CA; Hoffman MT; Lock TM; Fielbelkorn K; Coles EK; Panahon CJ; Steiner RL; Meichenbaum DL; Onyango AN; Morse GD
    Pediatrics; 2001 Jun; 107(6):E105. PubMed ID: 11389303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of reboxetine in the treatment of attention-deficit/hyperactivity disorder in boys with intolerance to methylphenidate: an open-label, 8-week, methylphenidate-controlled trial.
    Cohen-Yavin I; Yoran-Hegesh R; Strous RD; Kotler M; Weizman A; Spivak B
    Clin Neuropharmacol; 2009; 32(4):179-82. PubMed ID: 19644227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.
    Markowitz JS; Straughn AB; Patrick KS
    Pharmacotherapy; 2003 Oct; 23(10):1281-99. PubMed ID: 14594346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: A double-blind, crossover trial.
    Efron D; Jarman F; Barker M
    Pediatrics; 1997 Dec; 100(6):E6. PubMed ID: 9382907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Delayed-Release and Extended-Release Methylphenidate on Caregiver Strain and Validation of Psychometric Properties of the Caregiver Strain Questionnaire: Results from a Phase 3 Trial in Children with Attention-Deficit/Hyperactivity Disorder.
    López FA; Faraone SV; Newcorn JH; Doll HA; Rhoten S; Lewis HB; Khan TF; DeSousa NJ; Sallee FR; Incledon B
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):179-186. PubMed ID: 33797983
    [No Abstract]   [Full Text] [Related]  

  • 17. Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
    Robinson DM; Keating GM
    Drugs; 2006; 66(5):661-8; discussion 669-70. PubMed ID: 16620143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does L-Methylfolate Supplement Methylphenidate Pharmacotherapy in Attention-Deficit/Hyperactivity Disorder?: Evidence of Lack of Benefit From a Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
    Surman C; Ceranoglu A; Vaudreuil C; Albright B; Uchida M; Yule A; Spencer A; Boland H; Grossman R; Rhodewalt L; Fitzgerald M; Biederman J
    J Clin Psychopharmacol; 2019; 39(1):28-38. PubMed ID: 30566416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder.
    Wolraich ML; Greenhill LL; Pelham W; Swanson J; Wilens T; Palumbo D; Atkins M; McBurnett K; Bukstein O; August G
    Pediatrics; 2001 Oct; 108(4):883-92. PubMed ID: 11581440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.